Korea, US agree on delay linkage of drug approval and patent by 3 years

Korea and the United States have agreed to delay a system to suspend the approval process of a generic drug when the original developer files a complaint about patent violation against a generic maker that applies for product approval, by three years.

The two countries hammered out a revised free trade deal Friday, ending a three-year stalemate over U.S. demands for wider access to the Korea...